ReviewHerzschrittmachertherapie & Elektrophysiologie2018
Nanostim-leadless pacemaker.
Review in Herzschrittmachertherapie & Elektrophysiologie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Preferences of Patients and Cardiologists Regarding Pacemaker Characteristics in Spain: A Discrete Choice Experiment.Patient preference and adherence · 2026Article
- Implantable Biosensors for Vascular Diseases: Directions for the Next Generation of Active Diagnostic and Therapeutic Medical Device Technologies.Biosensors · 2025Review
- An approach to the removal of a leadless pacemaker with proximal and distal generator adherence to the myocardium.HeartRhythm case reports · 2025Article
- Improving outcomes in single chamber leadless pacemakers: strategies for minimizing vascular complications.BMC cardiovascular disorders · 2023Observational
- Electrical Stimulation for Low-Energy Termination of Cardiac Arrhythmias: a Review.Cardiovascular drugs and therapy · 2023Review
- Design and Implementation of Multisite Stimulation System Using a Double-Tuned Transmitter Coil and Miniaturized Implants.IEEE microwave and wireless technology letters · 2023Article
- Leadless Pacing: Therapy, Challenges and Novelties.Arrhythmia & electrophysiology review · 2023Review
- Smart Pacemaker: A Review.Cureus · 2022Review
- UK Expert Consensus Statement for the Optimal Use and Clinical Utility of Leadless Pacing Systems on Behalf of the British Heart Rhythm Society.Arrhythmia & electrophysiology review · 2022Review
- Cardiac Electronic Devices: Future Directions and Challenges.Medical devices (Auckland, N.Z.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanostim™ (St. Jude Medical Inc., Saint Paul, MN, USA; now Abbott Medical Inc. Abbott Park, IL, USA) was the first self-contained intracardiac pacemaker to be implanted in a human patient. A total of 1423 Nanostim devices were implanted worldwide between 2013 and 2016 and three clinical trials were initiated. Although the device was recalled in 2016 owing to rare but serious battery failures, the concept of leadless pacing has gained widespread acceptance and is expanding beyond the initial single-chamber devices to dual-chamber systems, biventricular pacing, and combinations with defibrillators. This review describes the design, results from initial clinical trials, and long-term experiences with Nanostim. It discusses the lessons learned from the pioneering device's successes and shortcomings, many of which are valid for leadless pacemakers in general. This article also considers the Nanostim experience in comparison with the early years of clinical use for other pioneering device therapies. Important questions include how to minimize the risk for short-term complications by appropriate operator training and evaluation of suitable patients, what the long-term performance tells us about safety, as well as the necessity and feasibility of device explantation.
Indexed as
Identifiers
30341551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.